Technical Analysis for ZLAB - Zai Lab Limited
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 143.5 | -3.05% | -4.51 |
ZLAB closed down 8.65 percent on Tuesday, March 2, 2021, on 1.27 times normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Up | Down | Down |
Historical ZLAB trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Fell Below 50 DMA | Bearish | -3.05% | |
180 Bearish Setup | Bearish Swing Setup | -3.05% | |
Earnings Movers | Other | -3.05% | |
Multiple of Ten Bearish | Other | -3.05% | |
Inside Day | Range Contraction | -3.05% | |
Lower Bollinger Band Touch | Weakness | -3.05% | |
Oversold Stochastic | Weakness | -3.05% | |
Crossed Above 50 DMA | Bullish | -11.43% | |
Expansion Pivot Buy Setup | Bullish Swing Setup | -11.43% | |
Wide Range Bar | Range Expansion | -11.43% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Down 3% | 10 minutes ago | |
Down 2 % | 10 minutes ago | |
Down 1% | 10 minutes ago | |
Fell Below Lower Bollinger Band | 10 minutes ago | |
Bearish 180 Entry | 10 minutes ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/01/2021
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Infectious Diseases Natural Sciences Medication Chemical Substances Omadacycline
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Infectious Diseases Natural Sciences Medication Chemical Substances Omadacycline
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 193.54 |
52 Week Low | 43.06 |
Average Volume | 341,863 |
200-Day Moving Average | 103.08 |
50-Day Moving Average | 158.22 |
20-Day Moving Average | 170.48 |
10-Day Moving Average | 161.39 |
Average True Range | 9.59 |
ADX | 24.16 |
+DI | 21.63 |
-DI | 25.10 |
Chandelier Exit (Long, 3 ATRs ) | 158.69 |
Chandelier Exit (Short, 3 ATRs ) | 173.14 |
Upper Bollinger Band | 194.61 |
Lower Bollinger Band | 146.36 |
Percent B (%b) | 0.03 |
BandWidth | 28.31 |
MACD Line | -2.31 |
MACD Signal Line | 1.88 |
MACD Histogram | -4.183 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 172.39 | ||||
Resistance 3 (R3) | 174.13 | 167.74 | 168.33 | ||
Resistance 2 (R2) | 167.74 | 161.53 | 166.87 | 166.97 | |
Resistance 1 (R1) | 157.87 | 157.69 | 154.68 | 156.14 | 165.62 |
Pivot Point | 151.48 | 151.48 | 149.88 | 150.61 | 151.48 |
Support 1 (S1) | 141.62 | 145.27 | 138.42 | 139.88 | 130.40 |
Support 2 (S2) | 135.23 | 141.44 | 134.36 | 129.05 | |
Support 3 (S3) | 125.36 | 135.23 | 127.69 | ||
Support 4 (S4) | 123.63 |